2023

A group of excellence composed of IDIBELL researchers and Cardiology professionals from the HUB joins the CIBER of Cardiovascular Diseases

The group linked to IDIBELL investigates personalized precision strategies for the interdisciplinary approach to heart failure in its evolutionary phases. Their research will contribute to the objective of the CIBERCV: reduce the impact of cardiovascular diseases and develop actions of excellence in translational cardiovascular research and training.

A group of excellence composed of IDIBELL researchers and Cardiology professionals from the HUB joins the CIBER of Cardiovascular Diseases Read More »

Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure

The international group of scientists who have discovered the benefits of dapagliflozin in the treatment of heart failure, including Dr. Josep Comín, head of the IDIBELL BIO-Heart Research Group on Cardiovascular Diseases and the Cardiology Service of the Hospital de Bellvitge, has published new disaggregated results of this research in the leading scientific journals Nature Medicine and the Journal of the American College of Cardiology (JACC).

Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure Read More »

Two brain regions size could predict the psychological behavioral therapy effectiveness in children with OCD

A study by the Bellvitge Biomedical Research Institute (IDIBELL), the Bellvitge University Hospital, the University of Barcelona, and CIBERSAM observes that children with increased volume of two prefrontal cortex structures respond better to cognitive behavioral therapy.

Two brain regions size could predict the psychological behavioral therapy effectiveness in children with OCD Read More »

Allogeneic transplantation from a matched registry donor may have better results than that from a less well-matched relative

A study led by the Catalan Institute of Oncology and IDIBELL, published in the scientific journal ‘Transplantation and Cellular Therapy’, concludes that, whenever possible, it is better for the patient to receive a transplant from a highly compatible registry donor than from a haploidentical donor with a family relationship, but less compatible.

Allogeneic transplantation from a matched registry donor may have better results than that from a less well-matched relative Read More »

Viladecans Against Cancer donates €25,000 to IDIBELL for research into personalized medicine for this disease

The donation, the result of the solidarity campaigns organized by the Association throughout 2022, will be used to finance the generation of a new experimental model for the study of predisposition to cancer, a project based on personalized medicine, and the use of stem cells to modeling diseases.

Viladecans Against Cancer donates €25,000 to IDIBELL for research into personalized medicine for this disease Read More »

Identified four genes that increase the risk of suicidal thoughts and acts

Although further research is needed to determine whether the identification of genetic markers may lead to the development of new targeted treatments, these findings help to understand how these markers may condition the pathology of suicidal thoughts and actions.

Identified four genes that increase the risk of suicidal thoughts and acts Read More »

The Niemann-Pick Foundation finances a clinical trial of a drug to stop the cognitive deterioration of the disease

Today the Niemann-Pick Spain Foundation came to deliver the check for 71,056.25 euros that will fully finance a pilot study to determine the efficacy and safety of the drug Efavirenz to alleviate the cognitive deterioration of patients with this minority disease of genetic origin and for which there is currently no treatment. The event was

The Niemann-Pick Foundation finances a clinical trial of a drug to stop the cognitive deterioration of the disease Read More »

A study that identifies for the first time more than 100 new genetic factors linked to colorectal cancer

This is the largest study on the genetics of colorectal cancer risk. The study, carried out by a global consortium, with the participation of IDIBELL and the Catalan Institute of Oncology, opens new strategies for treatment and chemoprevention.

A study that identifies for the first time more than 100 new genetic factors linked to colorectal cancer Read More »

Scroll to Top